Gallagher Benefit Services continues to observe substantial escalations in health benefits costs, a trend that simultaneously presents significant challenges for employers striving to manage their workforces and financial outlays, while also creating robust opportunities for benefits advisors. This comprehensive assessment was delivered last week by William Ziebell, the chief executive officer of Gallagher’s employee benefits consulting and brokerage business, during a pivotal meeting with investors held by the parent company, Arthur J. Gallagher & Co. The proceedings of this investor briefing were streamed live, with a recording subsequently made available on the company’s investor relations website, offering transparency into the current state of the healthcare benefits landscape.
During his address, Ziebell meticulously detailed the rising expenditures impacting both fully insured group health insurance plans and the critical stop-loss policies that self-insured employers leverage to safeguard their plans against potentially catastrophic financial losses. His remarks underscored a pervasive upward trajectory in costs across the board, signaling a period of sustained pressure on employer-sponsored health programs.
Alarming Premium Hikes Across the Board
Ziebell provided concrete figures illustrating the severity of these cost increases. For stop-loss insurance, a vital safety net for self-insured entities, he reported average premium increases in the mid-teens, with some instances soaring above 20%. This translates into a substantial financial burden for companies that choose to self-insure their health plans, exposing them to greater volatility and the need for robust risk management strategies. The range of increases, from approximately 13% to over 20%, highlights a market undergoing significant hardening, where the cost of protecting against high-severity claims is escalating rapidly.
The fully insured market is also experiencing considerable pressure. Ziebell noted that renewals for fully insured plans at Gallagher’s largest carriers are exhibiting high single-digit to approximately 10% premium increases. This implies a spectrum of increases typically ranging from more than 7% to about 10%. While these percentages might appear lower than those for stop-loss, they represent a direct and unavoidable increase in operating expenses for a vast number of employers who rely on fully insured models, impacting their budgets and potentially forcing difficult decisions regarding employee benefits packages. The consistency of these increases across different insurance models underscores a systemic issue within the broader healthcare ecosystem.
Multifaceted Drivers Behind the Escalation
Ziebell attributed these pronounced trends to a confluence of factors, painting a complex picture of the underlying causes. Key among these drivers are increased utilization of healthcare services, including a surge in diagnostics and treatments, the ongoing consolidation among health providers, persistent hospital workforce shortages, and the burgeoning utilization of higher-cost prescription drugs, most notably the class of medications known as GLP-1s. He emphasized that these elevated health program cost pressures are not transient but are likely to persist in the near to intermediate-term, demanding strategic and proactive responses from employers and their benefits advisors.
Increased Utilization and Diagnostic Demands: The healthcare sector has witnessed a significant rebound in utilization following the COVID-19 pandemic. Many elective procedures and preventative screenings that were deferred during the pandemic years are now being pursued, leading to a surge in demand for medical services. Furthermore, advancements in diagnostic technologies and a growing emphasis on early detection contribute to a higher volume of tests and subsequent treatments. This increased engagement with the healthcare system, while beneficial for patient health outcomes, inevitably translates into higher costs for benefit plans. The complexity of modern medicine often necessitates more intricate and expensive diagnostic pathways, adding layers to the overall cost structure.
Health Provider Consolidation and Market Power: The landscape of healthcare providers has undergone significant transformation in recent years, marked by an accelerating trend of consolidation. Hospitals are acquiring physician practices, and larger health systems are merging, leading to fewer independent entities and greater market power concentrated in the hands of larger organizations. This consolidation often results in reduced competition, allowing consolidated providers to negotiate higher reimbursement rates from insurers and, consequently, higher costs for employers. Studies by organizations such as the American Medical Association have frequently linked provider consolidation to increased healthcare prices, as these larger entities face less pressure to compete on cost. The lack of robust competition diminishes the negotiating leverage of insurers and self-insured employers, contributing directly to premium and claims cost inflation.
Hospital Workforce Shortages and Labor Costs: The healthcare industry is grappling with severe workforce shortages, particularly among nurses and other frontline medical professionals. The strains of the pandemic exacerbated existing shortages, leading to widespread burnout and departures from the profession. This scarcity of skilled labor has driven up wages and the reliance on expensive contract or agency staff to maintain adequate staffing levels. Hospitals, facing higher labor costs, often pass these expenses onto payers through increased service charges. These elevated operational costs directly impact the claims paid by health plans, contributing to the overall rise in health benefits expenditures. The long-term nature of training and retaining healthcare professionals suggests this factor will remain a significant cost driver for the foreseeable future.
The Impact of High-Cost Drugs, Especially GLP-1s: The emergence and widespread adoption of highly effective, yet exceptionally expensive, prescription drugs represent another critical cost driver. Among these, GLP-1 agonists (glucagon-like peptide-1 receptor agonists), such as Ozempic, Wegovy, and Mounjaro, have become a major focal point. Initially developed for type 2 diabetes management, their efficacy in weight loss has led to a surge in prescriptions for obesity treatment. While these drugs offer significant health benefits for many patients, their high price tags—often exceeding $1,000 per month per patient—are exerting immense pressure on pharmacy benefits managers and employer-sponsored plans. The growing demand for these medications, coupled with their cost, has made them one of the fastest-growing categories of pharmacy spend, challenging plan sponsors to balance access to innovative treatments with financial sustainability.
The Tightening Stop-Loss Market and Strategic Responses
The conditions described by Ziebell, particularly the hardening of the stop-loss market, mean that employers are increasingly seeking sophisticated benefits strategy ideas. The average premium increases in the mid-teens to over 20% for stop-loss policies underscore a heightened risk environment for insurers. This environment is characterized by a greater frequency of high-cost claims and increased unpredictability.
In response, stop-loss insurers are evolving their underwriting practices. There is a discernible trend towards utilizing new analytical tools and data to "laser out" more patients. Lasering refers to the practice where an insurer excludes coverage for specific individuals or conditions that are deemed high-risk or high-cost, or applies a significantly higher deductible for claims related to those individuals/conditions. For example, if an employee has a pre-existing condition requiring expensive ongoing treatment, the stop-loss carrier might apply a higher specific deductible for that individual, effectively shifting more of the initial financial risk back to the self-insured employer. This strategy helps insurers mitigate their exposure to catastrophic losses but can leave employers vulnerable to substantial financial hits if not properly managed through alternative arrangements or increased self-retention. This phenomenon makes the expertise of benefits advisors even more crucial for employers navigating these complex underwriting terms.
Employers are currently grappling with a multifaceted challenge: managing medical inflation, containing pharmacy cost pressure, focusing on workforce retention, and navigating an ever-evolving regulatory landscape—all simultaneously. This confluence of pressures makes decision-making significantly more intricate. As Ziebell highlighted, the more complex these decisions become, the more employers rely on external advice, sophisticated analytics, and expert execution to optimize their benefits programs and control costs effectively.
Broader Industry Perspective and Chronology
Ziebell’s observations are not isolated but echo a broader consensus within the health benefits market regarding challenging conditions. The timeline of these concerns extends beyond Gallagher’s recent investor meeting.
Cigna’s Outlook: Brian Evanko, the president of Cigna, a major player in the health insurance sector, recently provided a similar forward-looking perspective. He stated his expectation that stop-loss prices will continue their upward surge through 2027, with a potential easing of increases only anticipated in 2028. This long-term projection from a prominent industry leader reinforces the expectation of sustained cost pressures for self-insured employers over the next several years, necessitating long-term strategic planning rather than short-term fixes.
Tokio Marine HCC’s Analysis: Adding to this chorus of concern, analysts at Tokio Marine HCC, a significant stop-loss issuer, have reported that 2025 stop-loss cost increase trends were surprisingly high, exceeding initial expectations. Their assessment suggests that the market will continue to tighten, indicating that the current conditions are not an anomaly but rather a persistent trend driven by fundamental changes in healthcare costs and utilization. These corroborating statements from diverse corners of the insurance industry underscore the pervasive nature of the challenges and the collective understanding that the market is undergoing a significant recalibration.
These statements, made in recent months, collectively paint a picture of a health benefits market under severe strain. The current trends represent an acceleration of cost increases that have historically plagued the U.S. healthcare system, exacerbated by post-pandemic utilization patterns, the introduction of groundbreaking but expensive therapies, and structural changes within the provider landscape.
Implications and Future Outlook
The persistent rise in health benefits costs carries significant implications for various stakeholders. For employers, these increases directly impact their bottom line, potentially reducing profitability or forcing trade-offs in other areas, such as wage increases or investment in innovation. The pressure to maintain competitive benefits packages to attract and retain talent, especially in a tight labor market, clashes with the imperative to control escalating costs. This dilemma can lead to employers considering higher deductibles, increased employee contributions, or a reduction in covered services, which could in turn affect employee satisfaction and access to care.
For employees, the implications could mean higher out-of-pocket expenses, greater financial responsibility for their healthcare, and potentially more limited access to certain treatments or providers. The burden of healthcare costs is increasingly being shared with employees, making benefits literacy and financial planning more critical than ever.
The current environment also highlights the increasing value of benefits advisors. Their role is evolving from transactional brokers to strategic partners who can provide deep analytics, innovative plan design strategies, vendor management expertise, and guidance on regulatory compliance. Advisors are crucial in helping employers explore alternatives such as direct contracting with providers, implementing robust wellness programs, leveraging telemedicine, and negotiating more favorable terms with carriers and pharmacy benefit managers. Data-driven insights are becoming indispensable for identifying cost drivers and implementing targeted interventions.
Looking ahead, the "near to intermediate-term" outlook suggests continued vigilance and adaptation will be necessary. While there is hope for some stabilization in stop-loss prices post-2027, the underlying drivers of healthcare cost inflation—demographic shifts, technological advancements, and the burden of chronic diseases—are likely to remain. Innovation in healthcare delivery, a greater emphasis on preventive care, and potential policy interventions aimed at controlling drug prices or provider consolidation could offer some relief in the long term. However, for the immediate future, employers and their benefits advisors must navigate a landscape defined by significant cost pressures and the need for sophisticated, data-driven strategies to ensure sustainable and competitive employee health benefits. The era of passive benefits management is definitively over, replaced by a dynamic environment demanding proactive and expert engagement.
